Assertio Therapeutics ( (ASRT) ) has released its Q1 earnings. Here is a breakdown of the information Assertio Therapeutics presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Assertio Holdings, Inc. is a pharmaceutical company specializing in commercial capabilities, offering differentiated products in oncology, neurology, and pain management. The company recently released its first-quarter 2025 financial results, highlighting net product sales of $26.0 million, aligning with its 2025 outlook. Assertio is focused on sustainable growth and long-term value creation through strategic priorities such as reducing legal exposure, simplifying corporate structure, and prioritizing investment in growth assets.
In the first quarter, Assertio settled multiple legal matters, simplified its corporate structure, and reallocated resources towards growth assets like Rolvedon and Sympazan. Despite a decrease in overall net product sales from the previous year, Rolvedon sales exceeded internal expectations, and Sympazan prescriptions increased by 6.5% year-over-year. However, the company reported a net loss of $13.5 million, with adjusted EBITDA dropping to $0.2 million from $7.4 million in the prior year.
The company experienced a decrease in Rolvedon and Indocin sales due to pricing pressures and generic competition, respectively. Despite these challenges, Assertio improved its gross margin to 70% and increased SG&A expenses primarily due to higher legal costs. The company’s cash position decreased to $87.3 million, influenced by the timing of accounts receivable collections.
Looking ahead, Assertio remains committed to its strategic initiatives, focusing on enhancing its commercial platform and divesting non-core assets. The management is optimistic about the continued demand for Rolvedon and the effectiveness of the revised Sympazan promotional strategy, aiming for increased sales and operational efficiency in the coming quarters.